Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leukotriene generation and clinical implications.

Jonathan P Arm1

  • 1Department of Medicine, Harvard Medical School, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

Allergy and Asthma Proceedings
|April 2, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monocytes and Macrophages in Asthma.

International archives of allergy and immunology·2021
Same author

Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses.

The Journal of allergy and clinical immunology·2016
Same author

Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.

The Journal of allergy and clinical immunology·2015
Same author

LTC4 synthase polymorphism modifies efficacy of botanical seed oil combination in asthma.

SpringerPlus·2014
Same author

Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis.

The Journal of allergy and clinical immunology·2014
Same author

Impact of botanical oils on polyunsaturated fatty acid metabolism and leukotriene generation in mild asthmatics.

Lipids in health and disease·2013
Same journal

Key factors in the diagnosis of sesame allergy in children.

Allergy and asthma proceedings·2026
Same journal

Immunoglobulin E-mediated pumpkin seed allergy in children: Case series and narrative review with a structured literature search.

Allergy and asthma proceedings·2026
Same journal

Predictors of delayed treatment-free remission with omalizumab in chronic spontaneous urticaria.

Allergy and asthma proceedings·2026
Same journal

The digital front door: A national analysis of U.S. allergy and immunology fellowship program web sites.

Allergy and asthma proceedings·2026
Same journal

The impact of dietary patterns on the risk of asthma in children.

Allergy and asthma proceedings·2026
Same journal

The alpha-gal syndrome: Understanding the role of tick bites, and the delays in severe anaphylaxis.

Allergy and asthma proceedings·2026
See all related articles

Cysteinyl leukotrienes (LTs) play a key role in bronchial asthma pathogenesis. This review covers their biochemistry, role in asthma, and the effectiveness of LT-modifying drugs, including pharmacogenomics.

Area of Science:

  • Biochemistry
  • Immunology
  • Pharmacology

Background:

  • Cysteinyl leukotrienes (LTs) are critical mediators in inflammatory diseases.
  • Their role in bronchial asthma pathogenesis has been extensively studied over the past two decades.

Purpose of the Study:

  • To review the biochemistry of the 5-lipoxygenase pathway for LT generation.
  • To discuss the role of cysteinyl LTs in bronchial asthma.
  • To examine the efficacy of LT-modifying drugs and novel developments in LT research.

Main Methods:

  • Literature review of biochemical pathways and clinical studies.
  • Analysis of evidence for LT formation in asthmatic airways.
  • Discussion of pharmacogenomic aspects of 5-lipoxygenase and LTC4 synthase.

Related Experiment Videos

Main Results:

  • Cysteinyl LTs possess biological properties consistent with their involvement in asthma.
  • Evidence supports the formation of LTs in the airways of individuals with asthma.
  • LT-modifying drugs have demonstrated efficacy in managing bronchial asthma.

Conclusions:

  • Cysteinyl LTs are significant contributors to bronchial asthma.
  • Targeting LT pathways offers a viable therapeutic strategy for asthma management.
  • Pharmacogenomic approaches may personalize asthma treatment.